ATRC AtriCure, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1323885 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.8%
TTM net income YoY151.7%
TTM EPS YoY150.8%
Revenue 3-yr CAGR15.7%
Net income 3-yr CAGR—
Margins
Gross margin76.7%
Operating margin2.9%
Net margin2.5%
FCF margin9.0%
EBITDA margin4.9%
Returns
ROE2.9%
ROA2.2%
ROIC (approx.)3.9%
Asset turnover0.87x
Leverage & solvency
Liabilities / assets25.7%
Debt / equity0.11x
Current ratio4.33x
Interest coverage2.95x
Cash quality & payout
Operating cash flow / net income4.61x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue2.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $534.53M | $465.31M |
| Cost of revenue | $133.75M | $117.78M |
| Gross profit | $400.78M | $347.52M |
| R&D expense | $99.21M | $96.18M |
| SG&A expense | $311.02M | $291.36M |
| Operating income | -$9.45M | -$40.01M |
| Interest expense | $5.88M | $6.41M |
| Pretax income | -$10.16M | -$43.67M |
| Income tax | $1.28M | $1.02M |
| Net income | -$11.45M | -$44.70M |
| EBITDA | $2.64M | -$28.80M |
| EPS (basic) | -0.24 | -0.95 |
| EPS (diluted) | -0.24 | -0.95 |
| Weighted avg. shares (diluted) | 47.75M | 46.97M |
| Balance sheet | ||
| Cash & equivalents | $167.43M | $122.72M |
| Short-term investments | — | $0 |
| Receivables | $66.65M | $60.34M |
| Inventory | $78.49M | $75.33M |
| Current assets | $322.52M | $267.83M |
| PP&E, net | $39.12M | $41.66M |
| Goodwill | $234.78M | $234.78M |
| Intangibles | $48.03M | $56.47M |
| Total assets | $654.18M | $609.33M |
| Current liabilities | $81.52M | $73.42M |
| Short-term debt | — | $2.81M |
| Long-term debt | $61.87M | $61.87M |
| Total debt | $61.87M | $64.67M |
| Total liabilities | $162.24M | $148.36M |
| Shareholders' equity | $491.94M | $460.97M |
| Net debt | -$105.56M | -$58.05M |
| Shares outstanding | 49.79M | 48.87M |
| Cash flow statement | ||
| Operating cash flow | $57.33M | $12.20M |
| Capital expenditure | $9.05M | $11.46M |
| Free cash flow | $48.28M | $745,000 |
| Investing cash flow | -$14.55M | $30.23M |
| Financing cash flow | $1.18M | -$3.60M |
| Depreciation & amortization | $12.09M | $11.21M |
| Stock-based compensation | $44.69M | $40.41M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.